| Year |
Citation |
Score |
| 2019 |
Kurumaddali A, Salem AH, Agarwal SK. A Meta-Analysis of Higher-risk Myelodysplastic Syndrome Trials to Evaluate the Relationship between Short-term Endpoints and Overall Survival. Journal of Cancer. 10: 5427-5433. PMID 31632487 DOI: 10.7150/Jca.33175 |
0.452 |
|
| 2019 |
Agarwal S, Gopalakrishnan S, Mensing S, Potluri J, Hayslip J, Kirschbrown W, Friedel A, Menon R, Salem AH. Optimizing Venetoclax Dose in Combination with Low Intensive Therapies in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia: An Exposure-Response Analysis. Hematological Oncology. PMID 31251400 DOI: 10.1002/Hon.2646 |
0.522 |
|
| 2019 |
Salem AH, Dave N, Marbury T, Hu B, Miles D, Agarwal SK, Bueno OF, Menon RM. Pharmacokinetics of the BCL-2 Inhibitor Venetoclax in Subjects with Hepatic Impairment. Clinical Pharmacokinetics. PMID 30949874 DOI: 10.1007/S40262-019-00746-4 |
0.462 |
|
| 2019 |
Wei AH, Strickland SA, Hou JZ, Fiedler W, Lin TL, Walter RB, Enjeti A, Tiong IS, Savona M, Lee S, Chyla B, Popovic R, Salem AH, Agarwal S, Xu T, et al. Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1801600. PMID 30892988 DOI: 10.1200/Jco.18.01600 |
0.521 |
|
| 2018 |
Agarwal SK, Tong B, Bueno OF, Menon RM, Salem AH. Effect of Azithromycin on Venetoclax Pharmacokinetics in Healthy Volunteers: Implications for Dosing Venetoclax with P-gp Inhibitors. Advances in Therapy. PMID 30264382 DOI: 10.1007/S12325-018-0793-Y |
0.477 |
|
| 2018 |
Lee JS, Roberts A, Juarez D, Vo TT, Bhatt S, Herzog LO, Mallya S, Bellin RJ, Agarwal SK, Salem AH, Xu T, Jia J, Li L, Hanna JR, Davids MS, et al. Statins enhance efficacy of venetoclax in blood cancers. Science Translational Medicine. 10. PMID 29899021 DOI: 10.1126/Scitranslmed.Aaq1240 |
0.47 |
|
| 2017 |
Cheung TT, Salem AH, Menon RM, Munasinghe WP, Bueno OF, Agarwal SK. Pharmacokinetics of the BCL-2 Inhibitor Venetoclax in Healthy Chinese Subjects. Clinical Pharmacology in Drug Development. PMID 29058801 DOI: 10.1002/Cpdd.395 |
0.506 |
|
| 2017 |
Kumar S, Kaufman JL, Gasparetto C, Mikhael J, Vij R, Pegourie B, Benboubker L, Facon T, Amiot M, Moreau P, Punnoose EA, Alzate S, Dunbar M, Xu T, Agarwal SK, et al. Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma. Blood. PMID 29018077 DOI: 10.1182/Blood-2017-06-788786 |
0.319 |
|
| 2017 |
Agarwal SK, Mangal N, Menon RM, Freise KJ, Salem AH. Response Rates as Predictors of Overall Survival: A Meta-Analysis of Acute Myeloid Leukemia Trials. Journal of Cancer. 8: 1562-1567. PMID 28775775 DOI: 10.7150/Jca.18686 |
0.441 |
|
| 2017 |
Salem AH, Dunbar M, Agarwal SK. Pharmacokinetics of venetoclax in patients with 17p deletion chronic lymphocytic leukemia. Anti-Cancer Drugs. PMID 28562380 DOI: 10.1097/Cad.0000000000000522 |
0.544 |
|
| 2017 |
Agarwal SK, DiNardo CD, Potluri J, Dunbar M, Kantarjian HM, Humerickhouse RA, Wong SL, Menon RM, Konopleva MY, Salem AH. Management of Venetoclax-Posaconazole Interaction in Acute Myeloid Leukemia Patients: Evaluation of Dose Adjustments. Clinical Therapeutics. PMID 28161120 DOI: 10.1016/J.Clinthera.2017.01.003 |
0.509 |
|
| 2016 |
Liu H, Michmerhuizen MJ, Lao Y, Wan K, Salem AH, Sawicki J, Serby M, Vaidyanathan S, Wong SL, Agarwal S, Dunbar M, Sydor J, de Morais SM, Lee AJ. Absorption, Metabolism, and Excretion of a Novel Bcl-2 Inhibitor Venetoclax in Humans. Drug Metabolism and Disposition: the Biological Fate of Chemicals. PMID 27993930 DOI: 10.1124/Dmd.116.071613 |
0.485 |
|
| 2016 |
Salem AH, Hu B, Freise KJ, Agarwal SK, Sidhu DS, Wong SL. Evaluation of the Pharmacokinetic Interaction between Venetoclax, a Selective BCL-2 Inhibitor, and Warfarin in Healthy Volunteers. Clinical Drug Investigation. PMID 27910036 DOI: 10.1007/S40261-016-0485-9 |
0.496 |
|
| 2016 |
Agarwal SK, Salem AH, Danilov AV, Hu B, Puvvada S, Gutierrez M, Chien D, Lewis LD, Wong SL. Effect of Ketoconazole, a Strong CYP3A Inhibitor, on the Pharmacokinetics of Venetoclax, a BCL-2 Inhibitor, in Patients with Non-Hodgkin Lymphoma. British Journal of Clinical Pharmacology. PMID 27859472 DOI: 10.1111/Bcp.13175 |
0.498 |
|
| 2016 |
Salem AH, Agarwal SK, Dunbar M, Enschede SL, Humerickhouse RA, Wong SL. Pharmacokinetics of Venetoclax, a Novel BCL-2 Inhibitor, in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin's Lymphoma. Journal of Clinical Pharmacology. PMID 27558232 DOI: 10.1002/Jcph.821 |
0.565 |
|
| 2016 |
Jones AK, Freise KJ, Agarwal SK, Humerickhouse RA, Wong SL, Salem AH. Clinical Predictors of Venetoclax Pharmacokinetics in Chronic Lymphocytic Leukemia and Non-Hodgkin's Lymphoma Patients: a Pooled Population Pharmacokinetic Analysis. The Aaps Journal. PMID 27233802 DOI: 10.1208/S12248-016-9927-9 |
0.524 |
|
| 2016 |
Salem AH, Agarwal S, Dunbar M, Nuthalapati S, Chien D, Freise KJ, Wong SL. Effect of Low and High Fat Meals on the Pharmacokinetics of Venetoclax, a Selective First-in-Class Bcl-2 Inhibitor. Journal of Clinical Pharmacology. PMID 27029823 DOI: 10.1002/Jcph.741 |
0.477 |
|
| 2016 |
Agarwal SK, Hu B, Chien D, Wong SL, Salem AH. Evaluation of Rifampin's Transporter Inhibitory and CYP3A Inductive Effects on the Pharmacokinetics of Venetoclax, a Bcl-2 Inhibitor: Results of a Single- and Multiple-dose Study. Journal of Clinical Pharmacology. PMID 26953185 DOI: 10.1002/Jcph.730 |
0.532 |
|
| 2015 |
Agarwal SK, Kriel RL, Cloyd JC, Coles LD, Scherkenbach LA, Tobin MH, Krach LE. A pilot study assessing pharmacokinetics and tolerability of oral and intravenous baclofen in healthy adult volunteers. Journal of Child Neurology. 30: 37-41. PMID 25028414 DOI: 10.1177/0883073814535504 |
0.436 |
|
| 2013 |
Agarwal SK, Kriel RL, Brundage RC, Ivaturi VD, Cloyd JC. A pilot study assessing the bioavailability and pharmacokinetics of diazepam after intranasal and intravenous administration in healthy volunteers. Epilepsy Research. 105: 362-7. PMID 23561287 DOI: 10.1016/J.Eplepsyres.2013.02.018 |
0.592 |
|
| Show low-probability matches. |